1. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies
   Laurent Navarro et al, 2019, Bioorganic & Medicinal Chemistry CrossRef
2. Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents
   Wiwit Nurhidayah et al, 2022, Molecules CrossRef
3. ImprovedIn VivoStability of Radioiodinated Rituximab Using an Iodination Linker for Radioimmunotherapy
   Eun Jung Kim et al, 2016, Cancer Biotherapy and Radiopharmaceuticals CrossRef
4. Comparative cytotoxicity of 177Lu on various lung cancer cells and in vivo targeting of 177Lu-labeled cetuximab
   Kehong Li et al, 2023, Journal of Radioanalytical and Nuclear Chemistry CrossRef
5. Enhanced Transdermal Peptide‐Modified Flexible Liposomes for Efficient Percutaneous Delivery of Chrysomycin A to Treat Subcutaneous Melanoma and Intradermal MRSA Infection
   Yue Cai et al, 2023, Advanced Healthcare Materials CrossRef
6. Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules
   Weizhi Chen et al, 2019, Molecular Imaging CrossRef
7. The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
   Maryam Oroujeni et al, 2021, Pharmaceutics CrossRef
8. Immuno-PET for Clinical Theranostic Approaches
   Clément Bailly et al, 2016, International Journal of Molecular Sciences CrossRef
9. Radiolabeled Antibodies for Cancer Radioimmunotherapy
   Julie Rousseau et al, 2022, Nuclear Medicine and Immunology CrossRef